0 XP   0   0   0

GLENMARK PHARMACEUTICALS LTD.
Buy, Hold or Sell?

Should you buy, hold or sell GLENMARK PHARMACEUTICALS LTD.?

I guess you are interested in GLENMARK PHARMACEUTICALS LTD.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse GLENMARK PHARMACEUTICALS LTD.

Let's start. I'm going to help you getting a better view of GLENMARK PHARMACEUTICALS LTD.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is GLENMARK PHARMACEUTICALS LTD. even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how GLENMARK PHARMACEUTICALS LTD. is doing in the market. If the company is worth buying. The latest step is to find out how other investors value GLENMARK PHARMACEUTICALS LTD.. The closing price on 2023-01-27 was INR381.40 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
GLENMARK PHARMACEUTICALS LTD. Daily Candlestick Chart
GLENMARK PHARMACEUTICALS LTD. Daily Candlestick Chart
Summary









1. Valuation of GLENMARK PHARMACEUTICALS LTD.




Current price per share

INR381.40

2. Growth of GLENMARK PHARMACEUTICALS LTD.




Is GLENMARK PHARMACEUTICALS LTD. growing?

Current yearPrevious yearGrowGrow %
How rich?$1.1b$868.9m$248.7m22.3%

How much money is GLENMARK PHARMACEUTICALS LTD. making?

Current yearPrevious yearGrowGrow %
Making money$115.8m$119.3m-$3.4m-3.0%
Net Profit Margin7.7%8.9%--

How much money comes from the company's main activities?

3. Financial Health of GLENMARK PHARMACEUTICALS LTD.




Comparing to competitors in the Pharmaceuticals industry




  Industry Rankings (Pharmaceuticals)  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of GLENMARK PHARMACEUTICALS LTD..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit GLENMARK PHARMACEUTICALS LTD. earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Pharmaceuticals industry mean.
  • A Net Profit Margin of 7.7% means that ₹0.08 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 7.7%. The company is making a profit. +1
  • The TTM is 7.7%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ7.7%TTM7.7%0.0%
TTM7.7%YOY8.9%-1.2%
TTM7.7%5Y8.3%-0.7%
5Y8.3%10Y8.6%-0.2%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7%3.3%+4.4%
TTM7.7%6.9%+0.8%
YOY8.9%9.9%-1.0%
5Y8.3%6.3%+2.0%
10Y8.6%6.7%+1.9%
1.1.2. Return on Assets

Shows how efficient GLENMARK PHARMACEUTICALS LTD. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Pharmaceuticals industry mean.
  • 5.5% Return on Assets means that GLENMARK PHARMACEUTICALS LTD. generated ₹0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 5.5%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 5.5%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ5.5%TTM5.5%0.0%
TTM5.5%YOY6.2%-0.7%
TTM5.5%5Y6.0%-0.5%
5Y6.0%10Y6.1%-0.1%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ5.5%0.8%+4.7%
TTM5.5%1.3%+4.2%
YOY6.2%1.5%+4.7%
5Y6.0%1.4%+4.6%
10Y6.1%1.4%+4.7%
1.1.3. Return on Equity

Shows how efficient GLENMARK PHARMACEUTICALS LTD. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Pharmaceuticals industry mean.
  • 10.4% Return on Equity means GLENMARK PHARMACEUTICALS LTD. generated ₹0.10 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 10.4%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 10.4%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ10.4%TTM10.4%0.0%
TTM10.4%YOY13.7%-3.4%
TTM10.4%5Y13.4%-3.1%
5Y13.4%10Y15.1%-1.7%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ10.4%1.5%+8.9%
TTM10.4%2.0%+8.4%
YOY13.7%3.0%+10.7%
5Y13.4%2.1%+11.3%
10Y15.1%2.0%+13.1%

1.2. Operating Efficiency of GLENMARK PHARMACEUTICALS LTD..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient GLENMARK PHARMACEUTICALS LTD. is operating .

  • Measures how much profit GLENMARK PHARMACEUTICALS LTD. makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Pharmaceuticals industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y7.9%-7.9%
5Y7.9%10Y11.2%-3.4%
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ--5.6%+5.6%
TTM-0.5%-0.5%
YOY-6.2%-6.2%
5Y7.9%5.1%+2.8%
10Y11.2%5.2%+6.0%
1.2.2. Operating Ratio

Measures how efficient GLENMARK PHARMACEUTICALS LTD. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • An Operation Ratio of 1.24 means that the operating costs are ₹1.24 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 1.244. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.244. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.244TTM1.2440.000
TTM1.244YOY1.226+0.018
TTM1.2445Y1.247-0.002
5Y1.24710Y1.214+0.033
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2441.342-0.098
TTM1.2441.276-0.032
YOY1.2261.169+0.057
5Y1.2471.149+0.098
10Y1.2141.178+0.036

1.3. Liquidity of GLENMARK PHARMACEUTICALS LTD..

1.3. Liquidity
1.3.1. Current Ratio

Measures if GLENMARK PHARMACEUTICALS LTD. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A Current Ratio of 1.77 means the company has ₹1.77 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 1.766. The company is able to pay all its short-term debts. +1
  • The TTM is 1.766. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.766TTM1.7660.000
TTM1.766YOY1.752+0.014
TTM1.7665Y1.792-0.025
5Y1.79210Y1.781+0.011
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7662.205-0.439
TTM1.7662.010-0.244
YOY1.7522.125-0.373
5Y1.7921.812-0.020
10Y1.7811.786-0.005
1.3.2. Quick Ratio

Measures if GLENMARK PHARMACEUTICALS LTD. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Pharmaceuticals industry mean.
  • A Quick Ratio of 0.97 means the company can pay off ₹0.97 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 0.969. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.969. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.969TTM0.9690.000
TTM0.969YOY0.901+0.068
TTM0.9695Y1.038-0.069
5Y1.03810Y1.007+0.032
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9691.118-0.149
TTM0.9691.152-0.183
YOY0.9011.091-0.190
5Y1.0381.007+0.031
10Y1.0070.869+0.138

1.4. Solvency of GLENMARK PHARMACEUTICALS LTD..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of GLENMARK PHARMACEUTICALS LTD. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to Pharmaceuticals industry mean.
  • A Debt to Asset Ratio of 0.47 means that GLENMARK PHARMACEUTICALS LTD. assets are financed with 46.8% credit (debt) and the remaining percentage (100% - 46.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 0.468. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.468. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.468TTM0.4680.000
TTM0.468YOY0.547-0.079
TTM0.4685Y0.550-0.082
5Y0.55010Y0.588-0.038
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4680.381+0.087
TTM0.4680.379+0.089
YOY0.5470.417+0.130
5Y0.5500.398+0.152
10Y0.5880.399+0.189
1.4.2. Debt to Equity Ratio

Measures if GLENMARK PHARMACEUTICALS LTD. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare GLENMARK PHARMACEUTICALS LTD. to the Pharmaceuticals industry mean.
  • A Debt to Equity ratio of 88.0% means that company has ₹0.88 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 0.880. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.880. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.880TTM0.8800.000
TTM0.880YOY1.209-0.329
TTM0.8805Y1.242-0.362
5Y1.24210Y1.482-0.240
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8800.586+0.294
TTM0.8800.598+0.282
YOY1.2090.598+0.611
5Y1.2420.671+0.571
10Y1.4820.664+0.818

2. Market Valuation of GLENMARK PHARMACEUTICALS LTD.

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings GLENMARK PHARMACEUTICALS LTD. generates.

  • Above 15 is considered overpriced but always compare GLENMARK PHARMACEUTICALS LTD. to the Pharmaceuticals industry mean.
  • A PE ratio of 13.25 means the investor is paying ₹13.25 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The EOD is 11.428. Very good. +2
  • The MRQ is 13.250. Very good. +2
  • The TTM is 13.250. Very good. +2
Trends
Current periodCompared to+/- 
EOD11.428MRQ13.250-1.822
MRQ13.250TTM13.2500.000
TTM13.250YOY13.512-0.263
TTM13.2505Y14.490-1.240
5Y14.49010Y22.989-8.499
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD11.42840.785-29.357
MRQ13.25051.661-38.411
TTM13.25051.419-38.169
YOY13.51264.495-50.983
5Y14.49056.903-42.413
10Y22.98961.712-38.723
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of GLENMARK PHARMACEUTICALS LTD..

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The MRQ is 13.649. Seems overpriced? -1
  • The TTM is 13.649. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ13.649TTM13.6490.000
TTM13.649YOY10.808+2.841
TTM13.6495Y14.317-0.668
5Y14.31710Y20.836-6.518
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
MRQ13.6490.015+13.634
TTM13.6490.036+13.613
YOY10.8080.327+10.481
5Y14.3170.144+14.173
10Y20.8360.144+20.692

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of GLENMARK PHARMACEUTICALS LTD. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Pharmaceuticals industry mean).
  • A PB ratio of 1.37 means the investor is paying ₹1.37 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of GLENMARK PHARMACEUTICALS LTD.:

  • The EOD is 1.184. Good. +1
  • The MRQ is 1.373. Good. +1
  • The TTM is 1.373. Good. +1
Trends
Current periodCompared to+/- 
EOD1.184MRQ1.373-0.189
MRQ1.373TTM1.3730.000
TTM1.373YOY1.855-0.482
TTM1.3735Y2.019-0.646
5Y2.01910Y3.663-1.644
Compared to industry (Pharmaceuticals)
PeriodCompanyIndustry (mean)+/- 
EOD1.1842.248-1.064
MRQ1.3732.690-1.317
TTM1.3733.050-1.677
YOY1.8553.185-1.330
5Y2.0192.899-0.880
10Y3.6632.711+0.952
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GLENMARK PHARMACEUTICALS LTD. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--71.66071.6600%35.232+103%29.395+144%35.781+100%
Book Value Growth--1.2861.2860%1.164+11%1.133+13%1.156+11%
Book Value Per Share--322.029322.0290%250.369+29%236.852+36%191.463+68%
Book Value Per Share Growth--1.2861.2860%1.164+11%1.133+13%1.156+11%
Current Ratio--1.7661.7660%1.752+1%1.792-1%1.781-1%
Debt To Asset Ratio--0.4680.4680%0.547-14%0.550-15%0.588-20%
Debt To Equity Ratio--0.8800.8800%1.209-27%1.242-29%1.482-41%
Dividend Per Share--3.2853.2850%2.497+32%2.605+26%2.480+32%
Dividend Per Share Growth--1.3161.3160%1.028+28%1.071+23%1.053+25%
Eps--33.37433.3740%34.380-3%31.305+7%27.770+20%
Eps Growth--0.9710.9710%1.250-22%1.018-5%1.093-11%
Free Cash Flow Per Share--11.28911.2890%12.633-11%12.946-13%6.318+79%
Free Cash Flow Per Share Growth--0.8940.8940%0.773+16%3.147-72%1.340-33%
Free Cash Flow To Equity Per Share---7.157-7.1570%-3.024-58%-5.583-22%1.312-645%
Free Cash Flow To Equity Per Share Growth---0.367-0.3670%-5.210+1320%-1.617+341%-0.456+24%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---21.608--------
Intrinsic Value_10Y_min---14.106--------
Intrinsic Value_1Y_max--8.407--------
Intrinsic Value_1Y_min--8.169--------
Intrinsic Value_3Y_max--17.203--------
Intrinsic Value_3Y_min--16.391--------
Intrinsic Value_5Y_max--16.284--------
Intrinsic Value_5Y_min--15.612--------
Net Profit Margin--0.0770.0770%0.089-14%0.083-8%0.086-11%
Operating Margin----0%-0%0.079-100%0.112-100%
Operating Ratio--1.2441.2440%1.226+2%1.2470%1.214+3%
Pb Ratio1.184-16%1.3731.3730%1.855-26%2.019-32%3.663-63%
Pe Ratio11.428-16%13.25013.2500%13.512-2%14.490-9%22.989-42%
Peg Ratio--13.64913.6490%10.808+26%14.317-5%20.836-34%
Price Per Share381.400-16%442.200442.2000%464.550-5%457.100-3%587.717-25%
Price To Total Gains Ratio5.089-16%5.9005.9000%12.313-52%53.331-89%72.469-92%
Profit Growth--0.9710.9710%1.250-22%1.020-5%1.095-11%
Quick Ratio--0.9690.9690%0.901+8%1.038-7%1.007-4%
Return On Assets--0.0550.0550%0.062-11%0.060-8%0.061-10%
Return On Equity--0.1040.1040%0.137-25%0.134-23%0.151-32%
Revenue Growth--1.1241.1240%1.028+9%1.061+6%1.097+2%
Total Gains Per Share--74.94574.9450%37.728+99%32.000+134%38.261+96%
Total Gains Per Share Growth--1.9861.9860%1.9940%2.285-13%3.994-50%
Usd Book Value--1117657581.0001117657581.0000%868949121.000+29%822034018.200+36%664506133.333+68%
Usd Book Value Change Per Share--0.8810.8810%0.433+103%0.362+144%0.440+100%
Usd Book Value Per Share--3.9613.9610%3.080+29%2.913+36%2.355+68%
Usd Dividend Per Share--0.0400.0400%0.031+32%0.032+26%0.031+32%
Usd Eps--0.4110.4110%0.423-3%0.385+7%0.342+20%
Usd Free Cash Flow--39179805.00039179805.0000%43843965.000-11%44930522.400-13%24961401.333+57%
Usd Free Cash Flow Per Share--0.1390.1390%0.155-11%0.159-13%0.078+79%
Usd Free Cash Flow To Equity Per Share---0.088-0.0880%-0.037-58%-0.069-22%0.016-645%
Usd Price Per Share4.691-16%5.4395.4390%5.714-5%5.622-3%7.229-25%
Usd Profit--115830453.000115830453.0000%119320824.000-3%107918970.000+7%95975533.333+21%
Usd Revenue--1513503069.0001513503069.0000%1346103267.000+12%1300315139.400+16%1123326569.000+35%
Usd Total Gains Per Share--0.9220.9220%0.464+99%0.394+134%0.471+96%
 EOD+3 -2MRQTTM+0 -0YOY+23 -185Y+25 -1710Y+27 -15

3.2. Fundamental Score

Let's check the fundamental score of GLENMARK PHARMACEUTICALS LTD. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1511.428
Price to Book Ratio (EOD)Between0-11.184
Net Profit Margin (MRQ)Greater than00.077
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.969
Current Ratio (MRQ)Greater than11.766
Debt to Asset Ratio (MRQ)Less than10.468
Debt to Equity Ratio (MRQ)Less than10.880
Return on Equity (MRQ)Greater than0.150.104
Return on Assets (MRQ)Greater than0.050.055
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of GLENMARK PHARMACEUTICALS LTD. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose399.050
Total1/1 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-03-312019-03-312020-03-312021-03-312022-03-31
Long-term Assets Other  5,6302905,920-5,6003201,099,9001,100,220-17,053,580-15,953,360



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets170,832,880
Total Liabilities79,966,410
Total Stockholder Equity90,866,470
 As reported
Total Liabilities 79,966,410
Total Stockholder Equity+ 90,866,470
Total Assets = 170,832,880

Assets

Total Assets170,832,880
Total Current Assets82,823,480
Long-term Assets82,823,480
Total Current Assets
Cash And Cash Equivalents 14,105,260
Short-term Investments 328,750
Net Receivables 31,011,350
Inventory 26,794,970
Other Current Assets 67,220
Total Current Assets  (as reported)82,823,480
Total Current Assets  (calculated)72,307,550
+/- 10,515,930
Long-term Assets
Property Plant Equipment 46,117,190
Goodwill 600,190
Intangible Assets 22,253,790
Other Assets 16,867,780
Long-term Assets  (as reported)88,009,400
Long-term Assets  (calculated)85,838,950
+/- 2,170,450

Liabilities & Shareholders' Equity

Total Current Liabilities46,894,310
Long-term Liabilities29,557,370
Total Stockholder Equity90,866,470
Total Current Liabilities
Short-term Debt 3,700,000
Short Long Term Debt 10,986,050
Accounts payable 22,886,620
Other Current Liabilities 122,190
Total Current Liabilities  (as reported)46,894,310
Total Current Liabilities  (calculated)37,694,860
+/- 9,199,450
Long-term Liabilities
Long term Debt Total 27,717,380
Capital Lease Obligations 2,916,720
Long-term Liabilities  (as reported)29,557,370
Long-term Liabilities  (calculated)30,634,100
+/- 1,076,730
Total Stockholder Equity
Common Stock281,170
Retained Earnings 93,929,210
Capital Surplus 16,853,600
Other Stockholders Equity -20,197,510
Total Stockholder Equity (as reported)90,866,470
Total Stockholder Equity (calculated)90,866,470
+/-0
Other
Capital Stock282,170
Cash and Short Term Investments 14,105,260
Common Stock Shares Outstanding 282,168
Liabilities and Stockholders Equity 170,832,880
Net Debt 22,598,230
Net Invested Capital 127,569,960
Net Working Capital 35,929,170



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
86,336,030
96,875,060
108,359,950
122,119,710
130,209,550
132,956,470
146,848,070
156,035,770
170,832,880
170,832,880156,035,770146,848,070132,956,470130,209,550122,119,710108,359,95096,875,06086,336,030
   > Total Current Assets 
47,626,940
53,232,740
59,061,420
68,746,390
69,886,920
66,968,250
68,036,160
73,595,790
82,823,480
82,823,48073,595,79068,036,16066,968,25069,886,92068,746,39059,061,42053,232,74047,626,940
       Cash And Cash Equivalents 
7,947,990
7,637,350
8,571,210
10,563,640
12,333,560
9,362,780
11,102,750
11,380,950
14,105,260
14,105,26011,380,95011,102,7509,362,78012,333,56010,563,6408,571,2107,637,3507,947,990
       Short-term Investments 
148,150
107,680
0
0
1,792,460
1,968,720
696,560
763,990
328,750
328,750763,990696,5601,968,7201,792,46000107,680148,150
       Net Receivables 
22,586,780
27,324,270
24,926,460
30,562,960
30,431,590
28,279,110
28,665,630
25,720,550
31,011,350
31,011,35025,720,55028,665,63028,279,11030,431,59030,562,96024,926,46027,324,27022,586,780
       Inventory 
9,328,790
12,690,390
17,993,130
21,390,500
20,305,850
22,520,740
21,356,240
25,462,990
26,794,970
26,794,97025,462,99021,356,24022,520,74020,305,85021,390,50017,993,13012,690,3909,328,790
       Other Current Assets 
7,615,230
2,235,190
158,410
5,902,200
5,821,660
4,797,810
5,372,630
104,020
67,220
67,220104,0205,372,6304,797,8105,821,6605,902,200158,4102,235,1907,615,230
   > Long-term Assets 
0
0
0
53,373,330
60,322,630
69,820,130
78,811,910
82,439,980
88,009,400
88,009,40082,439,98078,811,91069,820,13060,322,63053,373,330000
       Property Plant Equipment 
17,628,130
20,569,490
24,622,860
27,451,480
28,891,500
33,321,800
40,683,440
41,755,730
46,117,190
46,117,19041,755,73040,683,44033,321,80028,891,50027,451,48024,622,86020,569,49017,628,130
       Goodwill 
602,040
579,700
574,800
478,920
521,040
547,350
528,990
580,110
600,190
600,190580,110528,990547,350521,040478,920574,800579,700602,040
       Long Term Investments 
183,660
171,180
281,630
243,330
0
0
0
0
0
00000243,330281,630171,180183,660
       Intangible Assets 
12,728,760
12,134,930
14,452,420
12,855,810
14,581,790
16,822,770
21,291,980
22,769,380
22,253,790
22,253,79022,769,38021,291,98016,822,77014,581,79012,855,81014,452,42012,134,93012,728,760
       Long-term Assets Other 
0
0
0
1,280
5,630
5,920
320
1,100,220
-15,953,360
-15,953,3601,100,2203205,9205,6301,280000
> Total Liabilities 
56,370,430
66,873,570
65,657,490
72,725,430
74,319,010
76,904,630
86,143,020
85,389,500
79,966,410
79,966,41085,389,50086,143,02076,904,63074,319,01072,725,43065,657,49066,873,57056,370,430
   > Total Current Liabilities 
29,491,660
37,112,900
40,017,630
27,038,840
32,878,930
40,210,940
41,259,830
42,010,200
46,894,310
46,894,31042,010,20041,259,83040,210,94032,878,93027,038,84040,017,63037,112,90029,491,660
       Short-term Debt 
32,669,720
37,999,320
7,874,180
1,871,890
2,950,440
3,030,240
4,425,970
5,130,150
3,700,000
3,700,0005,130,1504,425,9703,030,2402,950,4401,871,8907,874,18037,999,32032,669,720
       Short Long Term Debt 
32,669,720
37,999,320
39,881,060
47,236,580
4,976,070
8,749,140
8,256,400
7,986,120
10,986,050
10,986,0507,986,1208,256,4008,749,1404,976,07047,236,58039,881,06037,999,32032,669,720
       Accounts payable 
13,625,840
20,456,670
19,407,930
17,432,310
18,697,840
22,207,510
21,258,430
22,377,680
22,886,620
22,886,62022,377,68021,258,43022,207,51018,697,84017,432,31019,407,93020,456,67013,625,840
       Other Current Liabilities 
5,899,580
1,588,020
2,391,310
3,655,060
4,457,810
4,049,110
4,800,470
286,380
122,190
122,190286,3804,800,4704,049,1104,457,8103,655,0602,391,3101,588,0205,899,580
   > Long-term Liabilities 
0
0
0
45,690,820
41,443,780
36,628,900
44,887,110
43,382,840
29,557,370
29,557,37043,382,84044,887,11036,628,90041,443,78045,690,820000
       Long term Debt Total 
0
0
24,872,970
45,363,390
41,417,780
35,737,540
42,743,370
41,128,510
27,717,380
27,717,38041,128,51042,743,37035,737,54041,417,78045,363,39024,872,97000
       Capital Lease Obligations 
0
0
0
0
0
0
3,173,400
2,982,890
2,916,720
2,916,7202,982,8903,173,400000000
       Long-term Liabilities Other 
0
0
0
303,380
-10
6,300
4,680
6,920
311,870
311,8706,9204,6806,300-10303,380000
> Total Stockholder Equity
29,832,800
30,003,360
42,702,460
49,394,280
55,890,540
56,051,840
60,705,050
70,646,270
90,866,470
90,866,47070,646,27060,705,05056,051,84055,890,54049,394,28042,702,46030,003,36029,832,800
   Common Stock
271,220
271,290
282,160
282,170
282,170
282,170
282,170
282,170
281,170
281,170282,170282,170282,170282,170282,170282,160271,290271,220
   Retained Earnings 
27,196,980
30,927,870
37,586,930
46,020,400
49,248,720
57,604,790
64,751,910
74,208,630
93,929,210
93,929,21074,208,63064,751,91057,604,79049,248,72046,020,40037,586,93030,927,87027,196,980
   Accumulated Other Comprehensive Income 000000000
   Capital Surplus 
0
0
17,293,470
17,296,100
17,296,100
16,853,600
16,853,600
16,853,600
16,853,600
16,853,60016,853,60016,853,60016,853,60017,296,10017,296,10017,293,47000
   Treasury Stock000000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue123,049,030
Cost of Revenue-49,788,090
Gross Profit73,260,94073,260,940
 
Operating Income (+$)
Gross Profit73,260,940
Operating Expense-103,341,300
Operating Income15,791,350-30,080,360
 
Operating Expense (+$)
Research Development-
Selling General Administrative33,742,230
Selling And Marketing Expenses-
Operating Expense103,341,30033,742,230
 
Net Interest Income (+$)
Interest Income1,508,050
Interest Expense-2,980,990
Net Interest Income-2,886,640-1,472,940
 
Pretax Income (+$)
Operating Income15,791,350
Net Interest Income-2,886,640
Other Non-Operating Income Expenses-
Income Before Tax (EBT)14,412,46015,791,350
EBIT - interestExpense = -2,980,990
9,417,110
12,398,100
Interest Expense2,980,990
Earnings Before Interest and Taxes (ebit)-17,393,450
Earnings Before Interest and Taxes (ebitda)22,260,600
 
After tax Income (+$)
Income Before Tax14,412,460
Tax Provision-4,475,970
Net Income From Continuing Ops9,936,4909,936,490
Net Income9,417,110
Net Income Applicable To Common Shares9,417,110
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-2,886,640
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
NGU24-NYM.COMM
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGU24-NYM.COMM.

NGU24-NYM.COMM Daily Candlestick Chart
NGM24-NYM.COMM
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGM24-NYM.COMM.

NGM24-NYM.COMM Daily Candlestick Chart
NGQ24-NYM.COMM
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NGQ24-NYM.COMM.

NGQ24-NYM.COMM Daily Candlestick Chart
ISKJ.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ISKJ.MCX.

ISKJ.MCX Daily Candlestick Chart
CHKZ.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CHKZ.MCX.

CHKZ.MCX Daily Candlestick Chart
VSYD.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VSYD.MCX.

VSYD.MCX Daily Candlestick Chart
VRSB.MCX
6 hours ago

I found you a Golden Cross on the daily chart of VRSB.MCX.

VRSB.MCX Daily Candlestick Chart
TBRU.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBRU.MCX.

TBRU.MCX Daily Candlestick Chart
SNGSP.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SNGSP.MCX.

SNGSP.MCX Daily Candlestick Chart
RBCM.MCX
6 hours ago

I found you a Golden Cross on the daily chart of RBCM.MCX.

RBCM.MCX Daily Candlestick Chart
OKEY.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OKEY.MCX.

OKEY.MCX Daily Candlestick Chart
MTLR.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MTLR.MCX.

MTLR.MCX Daily Candlestick Chart
MRKZ.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MRKZ.MCX.

MRKZ.MCX Daily Candlestick Chart
KRKN.MCX
6 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of KRKN.MCX.

KRKN.MCX Daily Candlestick Chart
JNOS.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JNOS.MCX.

JNOS.MCX Daily Candlestick Chart
BLNG.MCX
6 hours ago

I found you a Golden Cross on the daily chart of BLNG.MCX.

BLNG.MCX Daily Candlestick Chart
ASSB.MCX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ASSB.MCX.

ASSB.MCX Daily Candlestick Chart
CSYZ.MU
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CSYZ.MU.

CSYZ.MU Daily Candlestick Chart
MOH.MU
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MOH.MU.

MOH.MU Daily Candlestick Chart
TBK.V
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TBK.V.

TBK.V Daily Candlestick Chart
UMDK.F
6 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of UMDK.F.

UMDK.F Daily Candlestick Chart
RY4C.BE
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of RY4C.BE.

RY4C.BE Daily Candlestick Chart
PLY.BE
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PLY.BE.

PLY.BE Daily Candlestick Chart
PDL.LSE
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
27F0.MU
6 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of 27F0.MU.

27F0.MU Daily Candlestick Chart